A5112881488- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- BRCA gene mutations in cancer
- Cardiac electrophysiology and arrhythmias
- Hemophilia Treatment and Research
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Heart Rate Variability and Autonomic Control
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Glioma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Cancer-related cognitive impairment studies
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- Cardiac Imaging and Diagnostics
King George's Medical University
2016-2025
Lala Lajpat Rai Memorial Medical College
2022
Institute of Medical Sciences
2022
National Health Systems Resource Centre
2021
Ottawa Hospital
2009-2020
University of Ottawa
1992-2018
Jawaharlal Institute of Post Graduate Medical Education and Research
2013-2017
Ottawa Regional Cancer Foundation
2003-2016
Netaji Subhash Chandra Bose Medical College
2014
Ganesh Shankar Vidyarthi Memorial Medical College
2013
Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) synergy preclinical studies. This international phase III trial compared tolerability of capecitabine/docetaxel therapy with docetaxel anthracycline-pretreated patients MBC.Patients were randomized to 21-day cycles capecitabine 1,250 mg/m(2) twice daily on days 1 14 plus 75 day (n = 255) or 100 256).Capecitabine/docetaxel resulted significantly superior time...
PURPOSE; Pertuzumab, a human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. Pertuzumab the approved HER2-targeted antibody trastuzumab have complementary mechanisms of action result in enhanced antitumor activity when combined. This phase II trial assessed efficacy safety profile combination patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based...
The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) 50% patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was result the or alone, we recruited third cohort who received without trastuzumab. We then investigated impact reintroducing to on monotherapy.Twenty-nine HER2-positive therapy (840 mg...
Abstract Objective : Studies in breast cancer patients indicate that chemotherapy may cause subtle cognitive disturbances some women, but the course is unclear. The current study evaluated effects of adjuvant post‐menopausal 1 year following completion treatment. Patients and methods Breast scheduled to receive ( n =53) completed comprehensive neuropsychological testing before commencing (T1), month after completing (T2), again later (T3). A control group women receiving hormonal therapy...
Abstract Purpose : The primary purpose of this study was to evaluate the cognitive effects adjuvant chemotherapy in post‐menopausal breast cancer patients. Patients and methods Breast patients scheduled receive ( n = 61) completed comprehensive testing before after treatment. A control group women receiving hormonal therapy 51) tested at comparable intervals. Results Mean scores for both patient groups were within normal range relative published norms on all tests time points, generally...
ObjectiveThis study was conducted to determine and compare the prevalence of coronary artery disease risk factors in both a rural an urban population Moradabad north India.
In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate efforts pathology, radiology, surgery and oncology. Surgery mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with risk metastasis. Imatinib 400 mg/day or without recommended first-line treatment recurrent metastatic GIST; higher dose may be considered in patients who progress, develop secondary resistance present specific genotypic characteristics....
Abstract Objective : The primary purpose of this study was to evaluate the cognitive effects adjuvant hormonal therapies in breast cancer patients. Participants and Methods Post‐menopausal patients scheduled receive tamoxifen ( n =31) or anastrozole =14) completed neuropsychological testing around time commencement treatment (T1), again 5–6 months later (T2). A sample healthy female volunteers =28) tested at comparable intervals. standardized regression‐based approach used assess change....
This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC).Women with MBC were randomly assigned 2:1 to receive 80 mg/m2 once every 3 weeks 5 mg twice per day (combination arm) or placebo (placebo arm), following a lead-in I trial. The primary end point was time progression (TTP).In all, 168 patients enrolled; 112 56 placebo. Median TTP numerically longer the combination arm than (8.1 v 7.1 months), but...
Introduction Current factor prophylaxis strategy practised in developed countries is not feasible resource constraint developing like India. Aim The aim of this study was to investigate the efficacy and safety very low‐dose Methods Children 1–10 years age with severe haemophilia were randomized Prophylaxis group Episodic (On demand) group. received VIII (FVIII) concentrate, i.e. 10 units kg −1 body weights on 2 days a week. concentrate standard recommended doses. period 11.5 months. Results...
BackgroundThe addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients PALOMA-3. Here, we examined factors predictive long-term benefit.MethodsPremenopausal-peri/postmenopausal with endocrine-resistant, hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative MBC were randomised 2:1 (500 mg) and either (125 mg/d; 3/1 schedule; n = 347) or placebo (n 174). Baseline...
PURPOSE Preclinical studies indicate that metronomic chemotherapy is antiangiogenic and synergistic with other agents. We designed a phase I/II study to evaluate the safety activity of adding dalteparin prednisone cyclophosphamide methotrexate in women measurable metastatic breast cancer (MBC). PATIENTS AND METHODS Patients received daily oral cyclophosphamide, twice-weekly methotrexate, (dalCMP). The primary end point was clinical benefit rate (CBR), combination complete response (CR),...
Abstract Although COVID‐19 is no longer classified as a global emergency, the emergence of SARS‐CoV‐2 variants highlights urgent need for antiviral drug discovery. This study identifies potent inhibitors main protease, supporting future preparedness and advancing strategies. Using experimental drugs from ZINC ChEMBL libraries, systematic workflow combining SwissSimilarity‐based screening, molecular docking, dynamics (MD) simulations, density functional theory (DFT) calculations was employed...